The Anderson laboratory focuses on understanding how the immune response can be measured to detect and alter cancer development. The development of effective cancer immunotherapy requires identification of target antigens, and also an understanding of the mechanisms of immune regulation that limit effective immunotherapy. One challenge in tumor immunology is how to measure immune responses across the proteome. To address these issues, we have been developing methods to measure adaptive immune responses (antibodies and T cells) to cancers. We use custom protein microarrays and bead-array assays to detect serum antibodies, and have identified novel biomarkers for the detection of breast, ovarian, and human papillomavirus (HPV)-associated cancers. These biomarkers are being evaluated in large multicenter clinical studies, and are being adapted to point of care detection of cancer and infectious diseases for global health. We are also identify targets for cancer immunotherapy development.